A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-α) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation

Arnon Nagler^*, Raanan Berger, Aliza Ackerstein, Jaroslaw A. Czyz, Jose Luis Diez-Martin, Elizabeth Naparstek, Reuven Or, Shlomit Gan, Avichai Shimoni, Shimon Slavin

^*Corresponding author for this work

The Hematology Institute
Sheba Medical Center at Tel Hashomer
Hadassah University Medical Centre
Medical University of Gdańsk
Hospital General Universitario Gregorio Marañon
Tel Aviv Sourasky Medical Center
Top Ichilov at the Weizman Center

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-α) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-α) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation

Fingerprint

Keyphrases

Immunology and Microbiology

Neuroscience